# OncLive > OncLive - Healthcare Publication - Base URL: https://www.onclive.com - Generated: 2026-10-04T22:53:16.525Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.onclive.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.onclive.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.onclive.com/robots.txt](https://www.onclive.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Blood Club](https://www.onclive.com/blood-club) - [Breaking News](https://www.onclive.com/breaking-news) - [COVID-19](https://www.onclive.com/covid-19) - [Clinical](https://www.onclive.com/clinical) - [Clinical Trials in Focus](https://www.onclive.com//clinical-trials-in-focus) - [Conference](https://www.onclive.com/conference) - [Emerging Biomarker](https://www.onclive.com/emerging-biomarker) - [Events](https://www.onclive.com/events) - [Exhibitor](https://www.onclive.com/exhibitor) - [Immunotherapy in GU Cancers](https://www.onclive.com/immunotherapy-in-gu-cancers) - [Immunotherapy in Lung Cancer](https://www.onclive.com/immunotherapy-in-lung-cancer) - [Immunotherapy in Melanoma](https://www.onclive.com/immunotherapy-in-melanoma) - [Insights](https://www.onclive.com/insights) - [Insights Video Series](https://www.onclive.com/insights-video-series) - [Leukemia Experts Reflect on Defining Moments, Career Experiences, and Gender Bias as Women in the Field](https://www.onclive.com/leukemia-experts-reflect-on-defining-moments-career-experiences-and-gender-bias-as-women-in-the-field) - [Medical Content](https://www.onclive.com/medical-content) - [NO ADS](https://www.onclive.com/noads) - [National Fellows Forum](https://www.onclive.com/national-fellows-forum) - [News](https://www.onclive.com/news) - [Onc App Featured Content](https://www.onclive.com/app-featured-content) - [OncClub](https://www.onclive.com/oncclub) - [OncLive News Network®](https://www.onclive.com/news-network) - [OncLive Peer Exchange® ](https://www.onclive.com/peer-exchange) - [OncLive TV](https://www.onclive.com/onclive-tv) - [Oncology Nursing News](https://www.onclive.com/nurses) - [Podcasts](https://www.onclive.com/podcasts) - [Publications](https://www.onclive.com/publications) - [Rapid Readouts](https://www.onclive.com/rapid-readouts) - [Scientific Interchange & Workshop](https://www.onclive.com/scientific-interchange-and-workshop) - [Special Reports in Personalized Cancer Care](https://www.onclive.com/personalized-medicine) - [Sponsored](https://www.onclive.com/sponsored) - [The Talk](https://www.onclive.com/the-talk) - [Thoracic Night Live](https://www.onclive.com/thoracic-night-live) - [Video Series](https://www.onclive.com/video-series) - [Webinars](https://www.onclive.com/webinars) ## Featured Content - [Five Under 5: Top Oncology Videos for the Week of 9/27](https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-9-27): The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma. - [INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC](https://www.onclive.com/view/inbrx-106-plus-pembrolizumab-improves-responses-and-pfs-in-first-line-pd-l1-positive-hnscc): The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive... - [The OncFive: Top Oncology Articles for the Week of 9/27/2026](https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-9-27-2026): The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and... - [AUA Releases Guideline Amendment for NMIBC](https://www.onclive.com/view/aua-releases-guideline-amendment-for-nmibc): The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grad... - [FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL](https://www.onclive.com/view/fda-approves-pirtobrutinib-for-previously-untreated-cll-sll): The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion. - [FDA Approval Insights: Ropeginterferon Alfa-2b Ushers in Long-Awaited New Treatment Option for Essential Thrombocythemia](https://www.onclive.com/view/fda-approval-insights-ropeginterferon-alfa-2b-ushers-in-long-awaited-new-treatment-option-for-essential-thrombocythemia): Ruben Mesa, MD, FACP, details the significance of the FDA approval of ropeginterferon alfa-2b for essential thrombocythemia. - [UCSF’s Kevan Shokat Wins Stephenson Prize for Cancer Breakthrough](https://www.onclive.com/view/ucsf-s-kevan-shokat-wins-stephenson-prize-for-cancer-breakthrough): By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment. - [FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC](https://www.onclive.com/view/fda-grants-fast-track-designation-to-tre-515-plus-kras-inhibitors-in-pretreated-kras-g12c-nsclc): TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy... - [NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC](https://www.onclive.com/view/nda-submission-is-initiated-for-zipalertinib-plus-chemotherapy-in-frontline-egfr-exon-20-insertion-nsclc): An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data. - [OncLive Weekly News Quiz (10/2/2026): Did You Miss Crucial Lung Cancer, Breast Cancer, MDS, and PTLD Updates?](https://www.onclive.com/view/onclive-weekly-news-quiz-10-2-2026-did-you-miss-crucial-lung-cancer-breast-cancer-mds-and-ptld-updates-): Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz. ## Feeds and Indexes - [RSS Feed](https://www.onclive.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.onclive.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.onclive.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.onclive.com/authors): Browse all contributors and their published work